Navigation Links
Medivation Announces Participation in 13th Annual BIO CEO & Investor Conference
Date:2/7/2011

SAN FRANCISCO, Feb. 7, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, at 10:30 a.m. Eastern Time at the Waldorf-Astoria in New York.

Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.

Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Global ENT (Ear, Nose, And ... 23.01 million in 2022, according to a new study ... population, increasing prevalence of ear, nose, and throat related ... target customer base are expected serve this market as ... to estimates published by the WHO, 15% of adult ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud ... predictive analytics technology, announces it is working with ... solutions for the new Lockheed Martin Healthcare Technology ... leading health information technology providers, medical technology companies ... collaboration and innovation to improve care in rapidly ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 13, 2007 -,Cytos Biotechnology AG (SWX:CYTN) reported ... with CYT003-QbG10, an immunotherapeutic,product candidate for the ... patients suffering from mild to moderate allergic,rhinitis ... The trial,investigated in a doubleblind setting the ...
... company Pharmaxis today announced the results,from its Phase ... Pulmonary Disease (COPD), a respiratory disease,affecting over 30 ... in 79 diagnosed COPD patients at 12,centres in ... to,determine if subjects that were positive to an ...
Cached Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4
(Date:7/31/2015)... ... ... New Energy Works Timberframers invites the public to join their timber frame ... 9am – 12pm. Timber frame raisings are special, celebrating both craft and ... culmination of months of effort, planning, fundraising, and dreaming takes shape. , “There’s ...
(Date:7/31/2015)... ... 2015 , ... Super-Sod wants to participate in planning new home lawns from ... the perfect fit for such a goal. Houzz is a social media site that ... dynamic site that spreads home and home garden design ideas when members share their ...
(Date:7/31/2015)... DE (PRWEB) , ... July 31, 2015 , ... ... term care client base, with the recent implementation of Microsoft Dynamics GP for ... in the industry, Intellitec is now supporting senior living communities in 16 states. ...
(Date:7/30/2015)... ... , ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the ... Expo held at the Caribe Royal All Suites Hotel and Convention Center in Orlando, ... the largest medical cannabis expo in the country and this year’s expo will be ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, ... an app invention that can help people during emergencies. , "The worldwide mobile ... and Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile ...
Breaking Medicine News(10 mins):Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5
... HealthDay Reporter , WEDNESDAY, Oct. 27 (HealthDay ... the vaccine that protects against bacterial meningitis, a U.S. ... the recommendation because the vaccine appears not to last ... U.S. Centers for Disease Control and Prevention,s Advisory Committee ...
... develops and spreads much more slowly than scientists have ... The finding indicates that there is a potentially broad ... "For the first time, we have a quantifiable estimate ... would be best to intervene," according to Christine Iacobuzio-Donahue, ...
... planning of care and stronger relationships with physicians are ... a study by a Queen,s University professor. , "High ... Canadian," says professor of Medicine and Epidemiology Daren Heyland, ... "But it,s not always happening. We know from international ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With October ... offers breast cancer survivors some guidance on what they ... Karen Syrjala, director of biobehavioral sciences and co-director of ... Center in Seattle, touches upon both the lingering physical ...
... Carolina (UNC) researchers report in the November issue of ... diagnostic testing are overused in treating chronic neck pain. ... for neck pain, such as therapeutic exercise. According to ... effectiveness of therapeutic exercise in treating chronic neck pain ...
... not considered effective treatment for KRAS (a gene)-mutated metastatic ... cancer not responding to chemotherapy and a certain variation ... longer overall and progression-free survival than patients with other ... issue of JAMA . "Recent retrospective ...
Cached Medicine News:Health News:Teens Should Get Meningitis Booster Shot: CDC Panel 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 3Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: